Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Soffer

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 11, 2021
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery diseaseFrancesco Franchi, Fabiana Rollini, Latonya Been, et al.
JACC. Cardiovascular Interventions|November 1, 2022
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 StudyFrancesco Franchi, Luis Ortega-Paz, Fabiana Rollini, et al.
Lipids in Health and Disease|November 28, 2021
A new phenotypic classification system for dyslipidemias based on the standard lipid panelMaureen Sampson, Rami A Ballout, Daniel Soffer, et al.
Circulation|March 13, 2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 StudyFrancesco Franchi, Fabiana Rollini, Jose Rivas Rios, et al.
Circulation|January 12, 2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionFrancesco Franchi, Fabiana Rollini, Andrea Rivas, et al.
JACC. Basic to Translational Science|June 2, 2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic TestingFrancesco Franchi, Fabiana Rollini, Jose Rivas, et al.
Archives of Medical Science : AMS|September 1, 2020
Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)Vincent A Pallazola, Vasanth Sathiyakumar, Jihwan Park, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 30, 2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapyMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Thrombosis and Haemostasis|August 31, 2019
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT StudyFrancesco Franchi, Fabiana Rollini, Emilio Garcia, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 11, 2021
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery diseaseFrancesco Franchi, Fabiana Rollini, Latonya Been, et al.
JACC. Cardiovascular Interventions|November 1, 2022
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 StudyFrancesco Franchi, Luis Ortega-Paz, Fabiana Rollini, et al.
Lipids in Health and Disease|November 28, 2021
A new phenotypic classification system for dyslipidemias based on the standard lipid panelMaureen Sampson, Rami A Ballout, Daniel Soffer, et al.
Circulation|March 13, 2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 StudyFrancesco Franchi, Fabiana Rollini, Jose Rivas Rios, et al.
Circulation|January 12, 2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionFrancesco Franchi, Fabiana Rollini, Andrea Rivas, et al.
JACC. Basic to Translational Science|June 2, 2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic TestingFrancesco Franchi, Fabiana Rollini, Jose Rivas, et al.
Archives of Medical Science : AMS|September 1, 2020
Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)Vincent A Pallazola, Vasanth Sathiyakumar, Jihwan Park, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 30, 2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapyMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Thrombosis and Haemostasis|August 31, 2019
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT StudyFrancesco Franchi, Fabiana Rollini, Emilio Garcia, et al.
Pageof 4